For those of you who have knowledge of such things, have you any idea how the GSK's EU patent for exon-51 might affect access to Eteplirsen (if Eteplirsen is granted approval first)? Does it mean that, even if granted approval, it cannot be sold/marketed in the EU?
You can share this discussion in two ways…
Share this link:
Send it with your computer's email program: Email this